Evaluation of the usefulness of anti-cholinergic and B(Beta)3 agonist in patients with OAB.
- Conditions
- Overactive bladder
- Registration Number
- JPRN-UMIN000008863
- Lead Sponsor
- Clinical Research Support Center Kyushu
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 400
Not provided
1)Patients who has contraindication of Imidafenacin 2)Patients who has contraindication of Mirabegron 3)Patients with urinary flow decreased 4)Patients with history of urinary retention 5)Patients with arrhythmia 6)Patients with hypokalemia 7)Patients with serious kidney dysfunction 8)Residual urine volume is more than 100mL 9)Patients with bladder cancer, urinary tract stones, symptomatic urinary tract infection, recurrent urinary tract infection and interstitial cystitis. 10)Patients with polyuria 11)Patients who have administered prohibited substances or done prohibited therapy within the 4 weeks before enrollment 12)Patients who have a urology or genital surgery within the 6 months before enrollment 13)Patients with history of resistance to anti-holinergic agents 14)Lower urinary tract symptoms aren't stable. 15)Any other patients who are regarded as unsuitable for this study by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of total OABSS score
- Secondary Outcome Measures
Name Time Method